Related Experiment Video
Updated: Aug 11, 2026
12:24
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
Published on: June 3, 2014
[Inhibitor development after changing FVIII/IX products in patients with haemophilia]
S Kocher1, G Asmelash, V Makki
1Hämophiliezentrum, Medizinische Klinik III, Institut für Transfusionsmedizin, JW-Goethe-Universitätsklinikum, Frankfurt am Main.
Hamostaseologie
|September 11, 2012
Summary
Changing factor VIII (FVIII) products did not increase inhibitor risk in haemophilia patients. This study found no correlation between FVIII product changes and inhibitor development over 12 months.
Area of Science:
- Hematology
- Immunology
- Pharmacology
Context:
- Haemophilia A treatment involves factor VIII (FVIII) replacement therapy.
- Development of neutralizing antibodies (inhibitors) is a significant complication.
- The impact of switching FVIII products on inhibitor development requires investigation.
Purpose:
- To investigate the relationship between changing factor VIII (FVIII) products and the risk of inhibitor development in haemophilia patients.
- To identify potential risk factors associated with inhibitor formation in this patient cohort.
Summary:
- A retrospective study analyzed 119 haemophilia patients with 198 FVIII product changes over 12 months.
- No patients developed inhibitors temporally associated with FVIII product switching.
- Frequent changes, switching between plasma-derived and recombinant FVIII, and other factors showed no increased inhibitor risk.
Impact:
- Findings suggest that switching FVIII products may not be a significant risk factor for inhibitor development.
- Provides evidence to inform clinical decisions regarding FVIII product selection and management in haemophilia.
- Highlights the need for continued monitoring and research into inhibitor development.
Related Concept Videos
00:46Feedback Inhibition
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...